Your browser doesn't support javascript.
loading
Non-cross-linking advanced glycation end products affect prohormone processing.
Brings, Sebastian; Mier, Walter; Beijer, Barbro; Kliemank, Elisabeth; Herzig, Stephan; Szendroedi, Julia; Nawroth, Peter P; Fleming, Thomas.
Afiliação
  • Brings S; Department of Endocrinology, Metabolism and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany.
  • Mier W; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Beijer B; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Kliemank E; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Herzig S; Department of Endocrinology, Metabolism and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany.
  • Szendroedi J; German Centre of Diabetes Research (DZD), Munich, Germany.
  • Nawroth PP; Institute for Diabetes and Cancer IDC Helmholtz Center Munich and Joint Heidelberg-IDC Translational Diabetes Program, Munich, Germany.
  • Fleming T; Department of Endocrinology, Metabolism and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany.
Biochem J ; 481(1): 33-44, 2024 Jan 10.
Article em En | MEDLINE | ID: mdl-38112318
ABSTRACT
Advanced glycation end products (AGEs) are non-enzymatic post-translational modifications of amino acids and are associated with diabetic complications. One proposed pathomechanism is the impaired processing of AGE-modified proteins or peptides including prohormones. Two approaches were applied to investigate whether substrate modification with AGEs affects the processing of substrates like prohormones to the active hormones. First, we employed solid-phase peptide synthesis to generate unmodified as well as AGE-modified protease substrates. Activity of proteases towards these substrates was quantified. Second, we tested the effect of AGE-modified proinsulin on the processing to insulin. Proteases showed the expected activity towards the unmodified peptide substrates containing arginine or lysine at the C-terminal cleavage site. Indeed, modification with Nε-carboxymethyllysine (CML) or methylglyoxal-hydroimidazolone 1 (MG-H1) affected all proteases tested. Cysteine cathepsins displayed a reduction in activity by ∼50% towards CML and MG-H1 modified substrates. The specific proteases trypsin, proprotein convertases subtilisin-kexins (PCSKs) type proteases, and carboxypeptidase E (CPE) were completely inactive towards modified substrates. Proinsulin incubation with methylglyoxal at physiological concentrations for 24 h resulted in the formation of MG-modified proinsulin. The formation of insulin was reduced by up to 80% in a concentration-dependent manner. Here, we demonstrate the inhibitory effect of substrate-AGE modifications on proteases. The finding that PCSKs and CPE, which are essential for prohormone processing, are inactive towards modified substrates could point to a yet unrecognized pathomechanism resulting from AGE modification relevant for the etiopathogenesis of diabetes and the development of obesity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Finais de Glicação Avançada / Diabetes Mellitus Limite: Humans Idioma: En Revista: Biochem J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Finais de Glicação Avançada / Diabetes Mellitus Limite: Humans Idioma: En Revista: Biochem J Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha